Huasaiberman, Peide Bio, and TYK Medicines Secure Tens of Millions in Funding; File IPO Prospectuses

Dec 30, 2023 15:35 CST Updated 15:35

HUASAIBIO

Developer of Stem Cell Therapy Products

PDBio

Peptide Innovation Drug Developer

Sino-cell Biomed: Completes Tens of Millions of Yuan in Series A Financing, Develops TIL Therapy for Solid Tumors

RecentlySino-cell Biomed announced that the company had completed a multi-million yuan A-round financing previously. Combined with the industrial support provided by the government, the company has received nearly 100 million yuan in capital injection.Public information shows that Sino-cell Biomed was established in March 2019 as an innovation-driven high-tech cell biopharmaceutical company.The company mainly starts from unmet clinical needs, focusing on developing innovative cell drugs, with an emphasis on TIL cell drugs for solid tumors.

TIL therapy refers to the process of isolating naturally infiltrating lymphocytes from tumor tissue, expanding them in vitro and optimizing their function, and then reinfusing them into the patient's body.TIL has multiple advantages, such as TCR clonality, selective tumor homing ability, and lower off-tumor targeting toxicity, making TIL therapy the most promising cellular immunotherapy to potentially conquer solid tumors.

At the end of November 2023, Sino-cell Biomed announced that its self-developed first Class 1 TIL cell new drug, HS-IT101 Injection, obtained the NMPA clinical trial implied permission, intended for development to treat advanced solid tumors.According to the official website of Sino-cell Biomed, HS-IT101 is an autologous natural enhanced TIL product.Leveraging the advantages of Sino-cell Biomed in process technology, the candidate drug boasts a cultivation success rate exceeding 95%.At the same time, HS-IT101 injection requires only a small amount of tumor tissue to meet production needs, has a short preparation cycle, and features low-dose interleukin-2 administration in clinical settings, which can significantly reduce the difficulty of clinical trials.

In addition, Sino-cell Biomed has also developed gene-modified super TIL products HS-IT201 and HS-IT301.According to the official website of Sino-cell Biomed, the Super TIL product combines lentivirus technology with gene logic regulation methods to precisely control the expression of target genes inserted into TIL. This type of product has already shown promising results in vitro and in organoids and is about to enter IIT clinical research.

PDBio: Completes Tens of Millions in Pre-A Round Financing, Accelerates R&D of Peptide New Drug Pipeline

Recently, PDBio successfully completed a Pre-A round of financing worth tens of millions of yuan, led by the Sichuan Development Academician Fund and followed by institutions such as Huaxi Securities. This round of financing will mainly be used for the research and development of new peptide drug pipelines.

PDBio was founded in May 2021, constructing a hundred-million-level natural peptide library from venomous animals. Based on the targeted mining system of animal venom peptides, the company screens and develops peptide drugs through a "high-throughput + cloud computing" screening platform and AI technology.

The company will independently research and develop new peptide drugs for anti-infective and cardiovascular disease indications; for candidate drugs of other indications, the company plans to primarily transfer them after reaching a certain stage of development.A technical system for large-scale mining of active peptides from animal venoms has been established, with more than 1,000 venomous animal species collected so far. Genomic, transcriptomic, peptidomic, and other multi-omics technologies are utilized to conduct omics analyses on venomous animal samples. Subsequently, a functional peptide screening technology system is applied to gather highly active peptide sequences.

Currently, the company has identified four candidate peptide drugs through targeted discovery, all of which are in the preclinical research stage. The pipelines targeting acne, pulmonary fibrosis, and antithrombotic therapies are expected to file IND applications successively in the next couple of years.

Sino-cell Biomed: Completes Nearly 200 Million RMB D-Round Financing

Recently,Tongyuan Kang Medicine Announces Completion of Nearly 200 Million RMB D-Round Financing.

Tongyuan Kang Pharmaceutical was established in November 2017. It has built a 30,000-square-meter new drug research and development center in Changxing Life Science Park, Huzhou, Zhejiang. Subsequently, the company set up its administrative headquarters, clinical medicine department, and business development department in Shanghai, established a small molecule drug screening platform in Zhengzhou, and owns a new drug preparation factory under construction in Changxing, Huzhou. It is one of the few innovative biopharmaceutical high-tech companies in China with both drug research and development and production capabilities.

Sino-cell Biomed has an international team of researchers and managers, with core executives averaging over 20 years of work experience, including 4 national experts, 4 provincial experts, and dozens of returned overseas experts and doctors.After six years of vigorous development, the company now has more than 140 employees and boasts a top-tier team covering the entire process, including drug discovery, DMPK evaluation, CMC, clinical, regulatory affairs, business development, and operations.

The company focuses on the development of Best-in-class & First-in-class small molecule anti-tumor drugs, among which TY-9591 has entered Phase II/III clinical trials;TY-302 has entered Phase II clinical trials;TY-2136b has entered Phase I clinical trials in the United States and was granted Orphan Drug Designation (ODD) by the FDA on September 20, 2023, supporting accelerated clinical development and registration for market approval.In addition, the company's RET, CDK7, CDK2/4/6, Exon20 and other pipelines have completed IND applications in both China and the United States, rapidly advancing to Phase I clinical trials.A series of innovative small molecule drugs targeting are undergoing IND applications in both China and the United States.In addition, with the expansion of scale, the company has recently extended its business line to the central nervous system (CNS) drug field, actively exploring leading targets both domestically and internationally, and is expected to obtain the first IND approval in this field in the near future.